Enanta Pharmaceuticals (NASDAQ:ENTA) was downgraded by analysts at ValuEngine from a “strong-buy” rating to a “buy” rating in a note issued to investors on Thursday.

Several other equities analysts have also recently issued reports on the company. Zacks Investment Research cut Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday. BidaskClub raised Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, November 2nd. Oppenheimer set a $100.00 price objective on Enanta Pharmaceuticals and gave the company a “hold” rating in a report on Tuesday, August 14th. UBS Group cut Enanta Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Wednesday, August 8th. Finally, JMP Securities reissued a “buy” rating and issued a $120.00 price objective on shares of Enanta Pharmaceuticals in a report on Tuesday, July 31st. One research analyst has rated the stock with a sell rating, five have issued a hold rating and three have assigned a buy rating to the stock. Enanta Pharmaceuticals has a consensus rating of “Hold” and a consensus price target of $104.00.

Shares of ENTA stock opened at $76.01 on Thursday. The stock has a market capitalization of $1.64 billion, a PE ratio of 83.53 and a beta of 1.04. Enanta Pharmaceuticals has a 52-week low of $44.52 and a 52-week high of $127.77.

Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its quarterly earnings data on Tuesday, August 7th. The biotechnology company reported $0.97 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.98 by ($0.01). The company had revenue of $57.26 million during the quarter, compared to analyst estimates of $56.59 million. Enanta Pharmaceuticals had a net margin of 37.63% and a return on equity of 25.84%. Sell-side analysts expect that Enanta Pharmaceuticals will post 3.59 earnings per share for the current year.

In related news, VP Nathalie Adda sold 4,155 shares of the company’s stock in a transaction dated Thursday, September 20th. The stock was sold at an average price of $95.32, for a total value of $396,054.60. Following the completion of the transaction, the vice president now owns 4,155 shares of the company’s stock, valued at approximately $396,054.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Tim Ocain sold 25,000 shares of the company’s stock in a transaction dated Monday, October 1st. The stock was sold at an average price of $83.64, for a total value of $2,091,000.00. The disclosure for this sale can be found here. Insiders sold a total of 33,310 shares of company stock valued at $2,870,644 in the last ninety days. 10.56% of the stock is currently owned by insiders.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ENTA. Wells Fargo & Company MN raised its holdings in Enanta Pharmaceuticals by 8.2% in the 1st quarter. Wells Fargo & Company MN now owns 25,306 shares of the biotechnology company’s stock worth $2,048,000 after purchasing an additional 1,918 shares during the period. UBS Group AG increased its stake in Enanta Pharmaceuticals by 1,246.0% during the 1st quarter. UBS Group AG now owns 27,769 shares of the biotechnology company’s stock worth $2,247,000 after buying an additional 25,706 shares in the last quarter. Legal & General Group Plc increased its stake in Enanta Pharmaceuticals by 3.1% during the 1st quarter. Legal & General Group Plc now owns 27,064 shares of the biotechnology company’s stock worth $2,175,000 after buying an additional 805 shares in the last quarter. Principal Financial Group Inc. increased its stake in Enanta Pharmaceuticals by 3.2% during the 1st quarter. Principal Financial Group Inc. now owns 113,524 shares of the biotechnology company’s stock worth $9,185,000 after buying an additional 3,565 shares in the last quarter. Finally, Xact Kapitalforvaltning AB purchased a new stake in Enanta Pharmaceuticals during the 2nd quarter worth approximately $290,000. 78.05% of the stock is owned by institutional investors.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, focuses on discovering and developing small molecule drugs for the treatment of viral infections and liver diseases. The company's research and development focuses on disease targets: hepatitis B virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and respiratory syncytial virus.

See Also: Cost of Capital

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Enanta Pharmaceuticals (NASDAQ:ENTA)

Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.